Pagebio, Tengrui Pharma, Alibaba Health Sign Strategic Deal on Pardaxin on July 17

According to Guizang Finance, Pagebio-B (02565), Tengrui Pharma, and Alibaba Health (00241) signed a strategic cooperation agreement on July 17 to accelerate the commercialization of Pardaxin (vidpanatide injection), an original Chinese innovative drug for treating adult type 2 diabetes. Under the partnership, Pagebio will handle research and development and product supply; Tengrui Pharma will lead national commercial promotion, market access, and channel development; Alibaba Health will provide online consultation, prescription transfer, pharmacist review, professional logistics, and patient services. Pardaxin is a once-weekly GLP-1 receptor agonist with a fixed treatment dose of 0.97 mg requiring no titration, enabling "therapeutic dose from the first injection." The collaboration aims to integrate offline professional marketing with online digital healthcare capabilities, accelerating Pardaxin's transition from regulatory approval to real-world market validation and volume expansion.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments